Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : Farxiga Treatment for Chronic Kidney Disease Gets US FDA Approval

05/02/2021 | 11:34pm EDT


ę MT Newswires 2021
All news about ASTRAZENECA PLC
12:28pFTSE 100 Delivers Weak Start to Week Despite Strong Mining Sector
DJ
11:09aASTRAZENECA : BYDUREON BCise (exenatide extended-release) approved in the US for..
AQ
10:32aTHE LATEST : France digests news of restaurant health passes
AQ
10:00aASTRAZENECA : BioNTech aims to develop mRNA-based malaria vaccine
RE
06:41aMixing AstraZeneca, Pfizer-BioNTech COVID-19 Doses Raises Antibodies, South K..
MT
06:18aASTRAZENECA : Opinion based on results from Ultomiris Phase III trial that showe..
PU
05:40aASTRAZENECA : India to miss end-July vaccination target as Bharat Biotech lags
RE
04:57aASTRAZENECA : European Regulator Recommends AstraZeneca's Blood Disorder Drug fo..
MT
03:55aASTRAZENECA : Mixed AstraZeneca-Pfizer shot boosts COVID antibody level - study
RE
03:44aCORONAVIRUS - TUNISIA : Belgium sends emergency aid to Tunisia in the fight agai..
AQ
More news
Financials (USD)
Sales 2021 31 752 M - -
Net income 2021 4 669 M - -
Net Debt 2021 10 816 M - -
P/E ratio 2021 32,5x
Yield 2021 2,46%
Capitalization 178 B 178 B -
EV / Sales 2021 5,93x
EV / Sales 2022 5,17x
Nbr of Employees 76 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 114,65 $
Average target price 132,21 $
Spread / Average Target 15,3%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC13.22%155 197
JOHNSON & JOHNSON9.16%432 430
ROCHE HOLDING AG12.39%325 975
PFIZER, INC.13.23%218 198
ELI LILLY AND COMPANY44.60%209 276
NOVARTIS AG1.10%207 246